Stoke Therapeutics (NASDAQ:STOK) Trading Up 9.7% – What’s Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s share price traded up 9.7% during mid-day trading on Wednesday . The stock traded as high as $9.56 and last traded at $9.52. 982,181 shares changed hands during trading, a decline of 11% from the average session volume of 1,100,906 shares. The stock had previously closed at $8.68.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Chardan Capital began coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $24.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partners started coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Trading Down 1.1 %

The company has a market capitalization of $495.80 million, a P/E ratio of -4.46 and a beta of 0.95. The company’s fifty day moving average is $11.58 and its 200 day moving average is $12.92.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Equities research analysts predict that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 13,945 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $178,217.10. Following the sale, the insider now directly owns 47,332 shares in the company, valued at $604,902.96. This represents a 22.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Jonathan Allan sold 9,696 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the transaction, the general counsel now owns 35,142 shares of the company’s stock, valued at $449,114.76. This trade represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,849 shares of company stock valued at $809,421. 11.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics during the second quarter worth about $29,000. Intech Investment Management LLC purchased a new position in Stoke Therapeutics in the 3rd quarter worth approximately $160,000. The Manufacturers Life Insurance Company grew its stake in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new position in shares of Stoke Therapeutics in the 3rd quarter worth $192,000. Finally, Profund Advisors LLC purchased a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at $201,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.